DK1656458T3 - Human autisme-susceptibilitetsgen og anvendelser deraf - Google Patents

Human autisme-susceptibilitetsgen og anvendelser deraf

Info

Publication number
DK1656458T3
DK1656458T3 DK04786410T DK04786410T DK1656458T3 DK 1656458 T3 DK1656458 T3 DK 1656458T3 DK 04786410 T DK04786410 T DK 04786410T DK 04786410 T DK04786410 T DK 04786410T DK 1656458 T3 DK1656458 T3 DK 1656458T3
Authority
DK
Denmark
Prior art keywords
autism
gene
diagnosis
prevention
treatment
Prior art date
Application number
DK04786410T
Other languages
Danish (da)
English (en)
Inventor
Joerg Hager
Anne Philippi
Elke Roschmann
Original Assignee
Integragen Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Integragen Sa filed Critical Integragen Sa
Application granted granted Critical
Publication of DK1656458T3 publication Critical patent/DK1656458T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G01N33/5023—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects on expression patterns
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5058—Neurological cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5091—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing the pathological state of an organism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/172—Haplotypes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Cell Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Public Health (AREA)
  • Microbiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Toxicology (AREA)
  • Food Science & Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Physics & Mathematics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Psychiatry (AREA)
DK04786410T 2003-08-22 2004-08-20 Human autisme-susceptibilitetsgen og anvendelser deraf DK1656458T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US49691703P 2003-08-22 2003-08-22
US49690003P 2003-08-22 2003-08-22
PCT/IB2004/002995 WO2005019474A2 (fr) 2003-08-22 2004-08-20 Gene humain de susceptibilite a l'autisme et ses utilisations

Publications (1)

Publication Number Publication Date
DK1656458T3 true DK1656458T3 (da) 2009-08-24

Family

ID=34221427

Family Applications (1)

Application Number Title Priority Date Filing Date
DK04786410T DK1656458T3 (da) 2003-08-22 2004-08-20 Human autisme-susceptibilitetsgen og anvendelser deraf

Country Status (10)

Country Link
US (1) US20070134664A1 (fr)
EP (1) EP1656458B1 (fr)
JP (1) JP2007503210A (fr)
AT (1) ATE431855T1 (fr)
AU (1) AU2004267247B2 (fr)
CA (1) CA2535754A1 (fr)
DE (1) DE602004021186D1 (fr)
DK (1) DK1656458T3 (fr)
PT (1) PT1656458E (fr)
WO (1) WO2005019474A2 (fr)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0504096D0 (en) * 2005-02-28 2005-04-06 Tipogen As Method
US20060258691A1 (en) * 2005-05-13 2006-11-16 Joseph Barbosa Methods and compositions for improving cognition
EP2089018A2 (fr) * 2006-11-07 2009-08-19 Lexicon Pharmaceuticals, Inc. Méthodes de traitement des troubles cognitifs et de la démence
CA2743542A1 (fr) * 2008-11-12 2010-05-20 University Of Utah Research Foundation Marqueurs genetiques associes a l'autisme
US20110237537A1 (en) * 2009-05-29 2011-09-29 Lombard Jay L Methods for assessment and treatment of mood disorders via single nucleotide polymorphisms analysis
WO2010138796A2 (fr) * 2009-05-29 2010-12-02 Genomind, Llc Méthodes d'évaluation et de traitement de la dépression via l'utilisation d'une analyse des polymorphismes nucléotidiques simples
US8355927B2 (en) 2010-11-05 2013-01-15 Genomind, Llc Neuropsychiatric test reports
WO2011066132A1 (fr) * 2009-11-24 2011-06-03 St. Jude Children's Research Hospital Utilisation d'une protéine sarcoplasmique de type 2 d'atpase-ca2+ pour le diagnostic et le traitement de troubles d'apprentissage ou mentaux
WO2012078602A2 (fr) * 2010-12-06 2012-06-14 Children's Medical Center Corporation Méthode de diagnostic et méthode de traitement des troubles du spectre autistique et de la déficience intellectuelle
US20140194310A1 (en) 2011-05-24 2014-07-10 Daniel H. Geschwind Genes dysregulated in autism as biomarkers and targets for therapeutic pathways
CN114019161B (zh) * 2021-11-08 2022-08-09 陕西脉元生物科技有限公司 抗camk2a自身抗体的试剂在制备诊断神经系统症状相关疾病的试剂盒中的应用

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4861719A (en) 1986-04-25 1989-08-29 Fred Hutchinson Cancer Research Center DNA constructs for retrovirus packaging cell lines
US5278056A (en) 1988-02-05 1994-01-11 The Trustees Of Columbia University In The City Of New York Retroviral packaging cell lines and process of using same
US5670488A (en) 1992-12-03 1997-09-23 Genzyme Corporation Adenovirus vector for gene therapy
CA2156725A1 (fr) 1993-02-22 1994-09-01 Warren S. Pear Production de retrovirus sans auxiliaire, a haut titre, par transfection transitoire
FR2712812B1 (fr) 1993-11-23 1996-02-09 Centre Nat Rech Scient Composition pour la production de produits thérapeutiques in vivo.
IL116816A (en) 1995-01-20 2003-05-29 Rhone Poulenc Rorer Sa Cell for the production of a defective recombinant adenovirus or an adeno-associated virus and the various uses thereof
US6013516A (en) 1995-10-06 2000-01-11 The Salk Institute For Biological Studies Vector and method of use for nucleic acid delivery to non-dividing cells
WO1998058082A1 (fr) * 1997-06-17 1998-12-23 University Of Rochester Polymorphismes genetiques qui sont associes a des troubles relevant de l'autisme
WO1999055915A2 (fr) * 1998-04-29 1999-11-04 The Government Of The United States Of America As Represented By The Secretary, Department Of Health And Human Services IDENTIFICATION DE POLYMORPHISMES DANS LA REGION PCTG4 DE Xq13
AU4989700A (en) * 1999-05-06 2000-11-21 Children's Hospital Of Los Angeles Autism gene
WO2003039342A2 (fr) * 2001-11-06 2003-05-15 Millennium Pharmaceuticals, Inc. Methodes et compositions de traitement de la douleur et des affections douloureuses au moyen des genes 577, 20739 ou 57145
CA2364106A1 (fr) * 2001-11-30 2003-05-30 Christopher Gillberg Polynucleotide et proteine impliques dans la synaptogenese, variants de ceux-ci, et leurs applications therapeutiques et diagnostiques

Also Published As

Publication number Publication date
WO2005019474A3 (fr) 2005-10-13
EP1656458B1 (fr) 2009-05-20
CA2535754A1 (fr) 2005-03-03
PT1656458E (pt) 2009-06-24
AU2004267247B2 (en) 2010-02-18
DE602004021186D1 (de) 2009-07-02
AU2004267247A1 (en) 2005-03-03
WO2005019474A2 (fr) 2005-03-03
ATE431855T1 (de) 2009-06-15
US20070134664A1 (en) 2007-06-14
EP1656458A2 (fr) 2006-05-17
JP2007503210A (ja) 2007-02-22

Similar Documents

Publication Publication Date Title
IL179751A0 (en) Human autism predisposition gene encoding a transcription factor and uses thereof
IL179831A0 (en) Human autism susceptibility gene encoding prkcb1 and uses thereof
WO2006087634A3 (fr) Gene humain de susceptibilite a l'autisme codant pour une kinase et utilisations de celui-ci
WO2014009733A3 (fr) Cibles thérapeutiques pour la maladie d'alzheimer
ATE383853T1 (de) Arylessigsäuren und verwandte verbindungen zur behandlung von alzheimer-krankheit
DK1656458T3 (da) Human autisme-susceptibilitetsgen og anvendelser deraf
WO2007132292A3 (fr) Thérapie pour la maladie d'alzheimer
BRPI0509477A (pt) compostos de sulfonamida para o tratamento de distúrbios neurodegenerativos
DK1863937T3 (da) Humant autisme-susceptibilitetsgen kodende for et transmembranprotein og anvendelser deraf
Kalkan et al. Association of MTHFR gene C677T mutation with recurrent aphthous stomatitis and number of oral ulcers
WO2006090288A3 (fr) Genes humains de predisposition a l'autisme codant pour un transporteur de neurotransmetteur et utilisations associees
WO2001020026A3 (fr) Polymorphismes du gene humain hpxr et leur utilisation dans des applications diagnostiques et therapeutiques
IL172229A (en) Use of pyrzolopyridines for the preparation of medicinal products to improve cognitive perception
WO2006003526A3 (fr) Gene humain de predisposition a l'autisme codant otoa et utilisations de celui-ci
WO2007071437A3 (fr) Compositions et méthodes pour traiter des troubles inflammatoires
DE60324414D1 (de) Humanes fettleibigkeit suszeptibilitätsgen und deren verwendungen
ATE443160T1 (de) Für einen spannungsgesteuerten kaliumkanal kodierendes humanes adipositas- suszeptibilitätssgen und dessen verwendung
Schuch et al. The Genetic Basis of Autism Spectrum Disorder
Abdelmoula et al. Mycobiota, neuro-cognitif disorders and behavioural impairments: is there a relationship?
Fraga et al. Aging, demented patients and polymorphisms in cytokine genes
AU3925701A (en) Polymorphisms in the human cyp2b6 gene and their use in diagnostic and therapeutic applications
Lee Genetic modifiers of Huntington's disease
WO2005021787A3 (fr) Gene humain de predisposition a l’obesite et ses utilisations
Cirrito Amyloid-β metabolism in the brain interstitial fluid of a mouse model of Alzheimer's disease